Mizuho analyst Uy Ear raised the firm’s price target on uniQure (QURE) to $60 from $30 and keeps an Outperform rating on the shares. The firm views the Phase 1/2 trial results of AMT-130 in Huntington’s Disease as “highly positive.” The results should support potential approval, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- uniQure price target raised to $65 from $30 at Wells Fargo
- UniQure (QURE) Stock Jumps 248% on Huntington’s Trial Results. Analysts Raise Price Targets
- uniQure Announces Positive Results for Huntington’s Study
- uniQure Secures $175 Million Loan Amendment
- uniQure’s Promising Advancements in Huntington’s Disease Treatment and Strong Financial Position Justify Buy Rating